Ph.D. Christian Hassig - 19 Aug 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Role: Chief Scientific Officer
Signature: /s/ Jessica Oien, Attorney-in-Fact for Christian Hassig, Ph.D.
Issuer symbol: BOLD
Transactions as of: 19 Aug 2024
Net transactions value: $0
Form type: 4
Filing time: 20 Aug 2024, 19:11:48 UTC
Previous filing: 27 Mar 2024
Next filing: 23 Jan 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BOLD	Stock Option	Disposed to Issuer		-10,256	-100%		0	19 Aug 2024	Common Stock	10,256	$3.71	Direct	F1, F2
transaction	BOLD	Stock Option	Disposed to Issuer		-62,820	-100%		0	19 Aug 2024	Common Stock	62,820	$4.10	Direct	F2, F3
transaction	BOLD	Stock Option	Disposed to Issuer		-94,871	-100%		0	19 Aug 2024	Common Stock	94,871	$4.10	Direct	F2, F4
transaction	BOLD	Stock Option	Disposed to Issuer		-76,173	-100%		0	19 Aug 2024	Common Stock	76,173	$8.19	Direct	F2, F5
transaction	BOLD	Stock Option	Disposed to Issuer		-48,703	-100%		0	19 Aug 2024	Common Stock	48,703	$16.00	Direct	F2, F6
transaction	BOLD	Stock Option	Award		+10,256			10,256	19 Aug 2024	Common Stock	10,256	$3.56	Direct	F1, F2, F7
transaction	BOLD	Stock Option	Award		+62,820			62,820	19 Aug 2024	Common Stock	62,820	$3.56	Direct	F2, F3, F7
transaction	BOLD	Stock Option	Award		+94,871			94,871	19 Aug 2024	Common Stock	94,871	$3.56	Direct	F2, F4, F7
transaction	BOLD	Stock Option	Award		+76,173			76,173	19 Aug 2024	Common Stock	76,173	$3.56	Direct	F2, F5, F7
transaction	BOLD	Stock Option	Award		+48,703			48,703	19 Aug 2024	Common Stock	48,703	$3.56	Direct	F2, F6, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vested as to 25% of the underlying shares on January 1, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter.
F2	On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged.
F3	The stock option vests in 48 substantially equal monthly installments beginning on July 7, 2021.
F4	The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023.
F5	The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024.
F6	The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024.
F7	The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability.